Rare variants in *PPARG* with decreased activity in adipocyte differentiation are associated with increased risk of type 2 diabetes

Amit R. Majithia[a,b,c], Jason Flannick[a], Peter Shahinian[a], Michael Guo[d], Mark-Anthony Bray[a], Pierre Fontanillas[a], Stacey B. Gabriel[a], GoT2D Consortium[2], NHGRI JHS/FHS Allelic Spectrum Project[2], SIGMA T2D Consortium[2], T2D-GENES Consortium[2], Evan D. Rosen[c,e], and David Altshuler[a,b,c,d,f,1]

[a]Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA 02142; [b]Department of Molecular Biology and Diabetes Unit, Massachusetts General Hospital, Boston, MA 02114; [c]Department of Medicine, Harvard Medical School, Boston, MA 02115; [d]Department of Genetics, Harvard Medical School, Boston, MA 02115; [e]Division of Endocrinology and Metabolism, Beth Israel Deaconess Medical Center, Boston, MA 02115; and [f]Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139

Peroxisome proliferator-activated receptor gamma (PPARG) is a master transcriptional regulator of adipocyte differentiation and a canonical target of antidiabetic thiazolidinedione medications. In rare families, loss-of-function (LOF) mutations in *PPARG* are known to cosegregate with lipodystrophy and insulin resistance; in the general population, the common P12A variant is associated with a decreased risk of type 2 diabetes (T2D). Whether and how rare variants in *PPARG* and defects in adipocyte differentiation influence risk of T2D in the general population remains undetermined. By sequencing PPARG in 19,752 T2D cases and controls drawn from multiple studies and ethnic groups, we identified 49 previously unidentified, nonsynonymous *PPARG* variants (MAF < 0.5%). Considered in aggregate (with or without computational prediction of functional consequence), these rare variants showed no association with T2D (OR = 1.35; $P = 0.17$). The function of the 49 variants was experimentally tested in a novel high-throughput human adipocyte differentiation assay, and nine were found to have reduced activity in the assay. Carrying any of these nine LOF variants was associated with a substantial increase in risk of T2D (OR = 7.22; $P = 0.005$). The combination of large-scale DNA sequencing and functional testing in the laboratory reveals that approximately 1 in 1,000 individuals carries a variant in *PPARG* that reduces function in a human adipocyte differentiation assay and is associated with a substantial risk of T2D.

Type 2 diabetes (T2D) is a common, complex disease caused by insulin resistance in multiple peripheral tissues combined with inadequate beta-cell response. In the general population, a nonsynonymous P12A variant in peroxisome proliferator-activated receptor gamma (PPARG), a transcriptional regulator of adipocyte differentiation and canonical target of antidiabetic thiazolidinediones, has been associated with decreased risk of T2D (1, 2). It has been challenging to document the impact of this common polymorphism on function in human cell-based assays. For P12A, the variant is very common, but the magnitude of effect on disease risk is modest (20% decreased risk of T2D) (3). In rare families with syndromic lipodystrophy, loss-of-function (LOF) mutations in *PPARG* that prohibit adipocyte differentiation in vitro, have been found that segregate with lipodystophy, insulin resistance, and T2D (4, 5). The magnitude of effect on individual and cellular phenotypes is strong, but the mutations are extremely rare. Whether LOF mutations in PPARG play a broader role in T2D, and whether these mutations implicate a role for adipocyte differentiation in T2D, have not previously been characterized.

More generally, exome sequencing now enables the systematic identification of all nonsynonymous variants, common and rare, in population and clinical cohorts. However, interpretation of rare variants—even those that alter protein sequence—is challenging: The overwhelming majority of nonsynonymous variants in any given sample are extremely rare, and only a minority alters protein

function. For example, the NHLBI exome Sequencing Project identified 285,000 nonsynonymous variants in 2,440 individuals (6). Eighty-two percent were previously uncharacterized and over half were observed in a single individual. Bioinformatic analysis predicted that only 2% significantly alter protein function.

We hypothesized that individuals in the general population might harbor rare, nonsynonymous variants in *PPARG*, that only a subset of these variants would alter function in an adipocyte differentiation assay, and that such variants might be associated with a risk of T2D. We further hypothesized that the effect of these variants on type 2 diabetes risk in the general population might in some cases be less severe than that estimated in individuals ascertained based on syndromic lipodystrophy (7). To evaluate this hypothesis we sequenced *PPARG* in 19,752 multiethnic T2D cases/control samples, characterized each nonsynonymous variant through parallel bioinformatic and experimental approaches, and compared the T2D risk of individuals carrying benign and LOF variants.

Results

Identification of Nonsynonymous *PPARG* Variants from the Population. After sequencing and analyzing all exons of *PPARG* in 19,752 multiethnic individuals (9,070 T2D cases and 10,682 controls;

Significance

Genome sequencing of individuals in the population reveals new mutations in almost every protein coding gene; interpreting the consequence of these mutations for human health and disease remains challenging. We sequenced the gene *PPARG*, a target of antidiabetic drugs, in nearly 20,000 individuals with and without type 2 diabetes (T2D). We identified 49 previously unidentified protein-altering mutations, characterized their cellular function in human cells, and discovered that nine of these mutations cause loss-of-function (LOF). The individuals who carry these nine LOF mutations have a sevenfold increased risk of T2D, whereas individuals carrying mutations we classify as benign have no increased risk of T2D.

GENETICS

), 53 nonsynonymous *PPARG* variants were observed. Only one of these variants (the well-studied *PPARG* P12A variant, rs1801282) demonstrated a minor allele frequency greater than 1% in any ancestry group we studied (). As expected, carriers of the common *PPARG* P12A variant showed a reduced risk of T2D, consistent with previous

Table 1. Rare, nonsynonymous variants in *PPARG* identified from 19,752 T2D case/controls

Location on chromosome 3	Base change	Amino acid change	Ancestral geography	Counts in controls	Counts in T2D cases	Bioinformatic prediction[†]	OR (95% CI)	P
12458632	G > T	A417S	European	0	1	Deleterious		
12447449	G > T	D230Y	South Asian	0	1	Deleterious		
12447410	G > A	E217K	Hispanic	0	1	Deleterious		
12458359	G > A	E326K	Hispanic	0	1	Deleterious		
12434116	T > G	F162V	European	0	1	Deleterious		
12434114	G > A	G161D	European	0	2	Deleterious		
12434179	C > T	H183Y	Hispanic	1	0	Deleterious		
12434133	C > G	I167M	European, European American	1	1	Deleterious		
12458374	A > G	I331V	South Asian	1	0	Deleterious		
12475511	A > G	K462R	Hispanic	0	1	Deleterious		
12475583	A > C	K486T	South Asian	1	1	Deleterious		
12434164	C > A	L178I	European	1	5	Deleterious		
12458466	G > C	L361F	European American	1	1	Deleterious	2.11	0.12
12475403	C > T	P426L	European	0	1	Deleterious	(0.82–5.45)	
12475486	C > G	P454A	Hispanic	4	2	Deleterious		
12422871	C > T	Q121*	European American	1	0	Deleterious		
12422929	G > A	R140H	Hispanic, African American	1	1	Deleterious		
12434126	G > C	R165T	European	0	2	Deleterious		
12447479	C > T	R240W	South Asian	1	0	Deleterious		
12458306	G > T	R308L	European	0	1	Deleterious		
12458516	G > A	R378K	European	0	1	Deleterious		
12475399	C > T	R425C	European	0	1	Deleterious		
12422908	C > A	S133Y	European	0	1	Deleterious		
12447507	C > G	S249*	European	0	1	Deleterious		
12458613	C > A	S410R	Hispanic	1	0	Deleterious		
12421260	C > G	S47C	East Asian	0	1	Deleterious		
12458335	G > A	V318M	European	0	1	Deleterious		
12447537	C > T	A259V	European American	1	0	Benign		
12458594	C > T	A404V	Hispanic	0	1	Benign		
12475457	C > T	A444V	European American	1	0	Benign		
12421391	G > A	A91T	African American	3	0	Benign		
12447572	G > A	D271N	European	0	1	Benign		
12421266	A > C	D49A	Hispanic	1	0	Benign		
12421267	T > G	D49E	African American	2	2	Benign		
12475490	A > G	E455G	European American	1	0	Benign		
12421355	G > A	E79K	European, East Asian	1	4	Benign		
12393119	A > G	I10V	South Asian	1	1	Benign		
12434131	A > G	I167V	European	0	1	Benign		
12447512	A > G	I251V	Hispanic	0	1	Benign		
12421253	A > T	I45F	African American	3	0	Benign		
12458511	G > A	M376I	European	0	2	Benign		
12421279	G > A	M53I	South Asian	1	0	Benign		
12422880	A > G	N124D	South Asian	1	0	Benign		
12475424	C > T	P433L	Hispanic, European	0	2	Benign		
12458611	A > T	S410C	European	0	1	Benign		
12421343	A > C	T75P	Hispanic	1	3	Benign		
12458209	G > A	V276I	European, Hispanic, African American, East Asian	5	6	Benign		
12458386	G > C	V335L	African American, Hispanic	11	9	Benign		
12421262	G > A	V48M	European American	1	0	Benign		
12421274	G > A	V52I	African American, East Asian, European	3	2	Benign		
12422856	T > G	Y116D	South Asian	1	0	Benign		
12458216	A > G	Y278C	European	0	1	Benign		

The variant position is based on human genome build NCBI36/hg18, and the amino acid position is based on the NCBI protein reference sequence NP_005028.4. Release notes for this genome build are available at www.ncbi.nlm.nih.gov/genome/guide/human/release_notes.html#b36. CI, confidence interval.
*Stop codon.
[†]Criteria for deleterious: A variant must have a mammalian conservation LOD score >10 and be categorized as damaging by Condel (17) (*Methods*).

reports (odds ratio = 0.85; 95% confidence interval 0.78–0.93; $P = 0.0006$) (3).

The remaining 52 variants were observed in 120 individuals (Table 1), yielding an aggregate frequency of 0.6% in the population. The most frequently occurring variant in any ethnic group, p.V335L, was observed at a frequency of 0.7% (20 individuals of African-American ancestry). The majority of the variants (33 of 52 or 63%) were observed in only a single individual. Nonsynonymous variants were identified in every ancestry group sampled: European, East Asian, South Asian, European American, African American, and Hispanic. Some variants were specific to individuals from one ethnic background, whereas others were observed in individuals across multiple ethnic backgrounds. Every individual with a rare, nonsynonymous *PPARG* was heterozygous for that variant and carried only one rare, nonsynonymous *PPARG* variant. The *PPARG* variants identified were distributed across the entire protein-coding region and included variants in all previously identified functional domains. Two variants (p.Q121* and p.S249*) were predicted to result in premature termination of the protein. Of the variants we identified, 49 are previously unidentified and 3 (p.R165T, p.V318M, and p.R425C) have been previously reported to segregate with disease in families with familial partial lipodystrophy 3 (FPLD3).

Association analysis for T2D was performed comparing individuals carrying any rare missense *PPARG* variant (with frequency <1% in the study sample) to those who carried no such variant; no significant association was observed (odds ratio of 1.36;

95% confidence interval 0.87–2.11; $P > 0.17$). Next, variants were classified as benign or deleterious (Table 1) based on bioinformatic annotation combining computational prediction, evolutionary conservation, and variant frequency (restricted to variants observed in a single individual or the less stringent minor allele frequency <0.1%). The strongest association was for variants classified as deleterious (odds ratio of 2.11; 95% confidence interval 0.82–5.45); again, the result was not nominally significant ($P > 0.12$) despite nearly 20,000 samples.

Functional Assessment of Nonsynonymous *PPARG* Variants. Recognizing that the majority of rare protein-coding variants are benign or very mildly deleterious, and that computational prediction remains imperfect (8), we set out to experimentally characterize the function of each nonsynonymous *PPARG* variant by genetic complementation in an assay measuring differentiation of human preadipocytes. Specifically, we developed a quantitative adipocyte differentiation assay in human Simpson–Golabi–Behmel syndrome (SBGS) preadipocytes by combining high-content microscopy with a custom automated image analysis pipeline (Fig. 1A). This assay compared favorably with standard triglyceride quantification methods using Oil Red O staining and extraction (Fig. 1B) with the advantages of accelerated throughput and an explicit measurement of total cell number. To isolate the effect of exogenous *PPARG* variants on adipocyte differentiation, preadipocytes were exposed to a submaximal differentiation mixture that only permitted differentiation in the


Fig. 1. High-throughput quantification of adipocyte differentiation in response to exogenous PPARγ. (A) Preadipocytes are cultured in 96-well plates, differentiated for 8 d, and stained for lipid (BODIPY) and nuclei (DAPI). Each well is imaged in a high-content microscope for lipid and nuclei. Adipocytes and undifferentiated cells are identified by the overlay of lipid and nuclei from automated image analysis. (B) Preadipocytes were plated at increasing density and differentiated. Parallel samples were subjected to image-based differentiation measurement or Oil Red O staining followed by lipid extraction and spectrophotometric quantification. (C) Preadipocyte differentiation in response to increasing doses of exogenous PPARγ with and without 3-isobutyl-1-methylxanthine (IBMX). (D) Gene expression levels in preadipocytes of endogenous and exogenous PPARγ in response to increasing doses of exogenous PPARγ. Error bars indicate ±1 SEM.

presence of functioning, exogenous PPARG (Fig. 1C) and maintained endogenous PPARG at background levels (Fig. 1D).

Each nonsynonymous *PPARG* variant identified from population-based sequencing was engineered into a construct in vitro, and tested for its ability to rescue adipocyte differentiation in SGBS preadipocytes (Fig. 2A). The empirical distribution of WT PPARG function in this assay was defined using multiple independent replicates of WT PPARG clones, with reduced function in the assay defined as adipocyte differentiation index falling below this null distribution in a one-tailed t test with a $P < 0.05$ threshold. Variants previously reported to be benign (Fig. 2A, blue bars) and to cause LOF (Fig. 2A, red bars) were generated and tested in parallel as positive and negative controls, respectively. Among these previously characterized variants, those characterized as benign (Fig. 2A, blue bars) stimulate adipocyte differentiation with similar efficacy as WT PPARG whereas those known to cause reduced protein activity (Fig. 2A, red bars) show decreased ability to stimulate adipocyte differentiation to varying degrees. Consistent with prior work, variants reported to segregate with disease in FPLD3 families show the most severe LOF with those that reside in the DNA binding domain (p.R165T, p.C159Y, and p.Y151C), almost completely inactivating PPARG (9–11).

Using this assay we classified the 53 missense variants observed in population screening. Forty-one of the rare missense variants were scored as benign when tested in the assay: they stimulated adipocyte differentiation in a manner that fell within the 95% confidence interval based on replicates of WT PPARG. (The common P12A variant was at the lower limit of the normal range.) However, 12 variants fell below the 95% confidence limit for WT PPARG constructs. Of the 12 with reduced activity, 3 were previously reported as LOF mutations observed in patients with lipodystrophy, and 9 were previously unidentified. Novel variants with reduced function were identified in the DNA binding, the hinge, and the ligand-binding domains of PPARG (Fig. 2B). Notably, whereas all previously identified mutations in the DNA-binding domain (from families segregating FPLD3) completely inactivate PPARG, in study samples

ascertained for common disease, two partial LOF variants were observed in the DNA-binding domain (p.R140H and p.E217K).

Each variant that displayed reduced activity in the assay was retested for the ability to stimulate adipocyte differentiation in the presence of varying doses of the PPARG agonist rosiglitazone. Consistent with previous reports (13), and the lack of clinical efficacy of thiazolidinediones in FPLD3, complete LOF variants are unresponsive even to 100-fold increased doses. In contrast, some of the variants observed as having reduced activity in the cellular assay (e.g., p.R140H, p.E217K, p.Y278C, and p.M376I) were rescued to WT levels using a higher dose (two- to fivefold) of rosiglitazone (Fig. 2B).

LOF Nonsynonymous *PPARG* Variants and T2D Risk in the Population. Based on the experimental classification of variants in the adipocyte differentiation assay, we repeated the analysis of association to T2D in individuals carrying benign and functional *PPARG* variants (Fig. 3). Of the 102 individuals harboring variants classified as benign, half occurred in cases and half in controls (52 T2D cases and 50 controls). In contrast, of the 16 individuals harboring variants that cause reduced function in the assay, 14 occurred in cases of T2D and only 2 in controls. The estimated risk of T2D was 1.17-fold (95% confidence interval 0.68–2.02) in carriers of a benign *PPARG* variant and 7.22-fold (95% confidence interval 1.79–29.02; $P = 0.005$) in carriers of a *PPARG* variant with reduced function in the assay. We examined the phenotypic characteristics of these 16 carriers (where phenotypic data were available; Table 2), but did not observe compelling evidence that these individuals were extreme outliers in the measured parameters.

Discussion

Based on a multiethnic sample of nearly 20,000 individuals, we estimate that (*i*) approximately 6 in 1,000 individuals carry an inherited rare coding variant in *PPARG*, (*ii*) 20% of these variants demonstrate reduced function in an adipocyte differentiation assay, and (*iii*) individuals who are heterozygous for the latter class of variants have an estimated sevenfold increased risk


Fig. 2. Experimental characterization of rare PPARγ variants identified from population sequencing. (*A*) Each PPARγ variant was generated and tested for its ability to rescue adipocyte differentiation in vitro. From left to right PPARγ variants are sorted by in vitro function in three groups: (*i*) WT from independent experiments, (*ii*) previously identified synthetic and human mutations, and (*iii*) variants identified in population based exon resequencing. Blue dashed lines denote the 95% confidence interval of WT function. (*B*) Roziglitazone (rozi) dose–response of PPARγ variants identified as LOF. The amino acid position along the PPARγ protein is shown. EC$_{50}$ WT denotes the rozi dose required to achieve 50% of maximal WT response. AD, activation domain; DBD, DNA-binding domain; LBD, ligand-binding domain. Error bars indicate ±1 SEM. Significant differences compared with WT are noted: *$P < 0.05$; **$P < 0.005$; ***$P < 0.0001$. ‡Variants identified in families with partial lipodystrophy.

Fig. 3. T2D case/control status in multiethnic individuals harboring nonsynonymous *PPARG* variants, according to PPARG function in vitro. Each point represents an individual variant; point size denotes the number of individuals carrying that variant. Function in vitro was determined by the ability of each variant to rescue adipocyte differentiation in comparison with WT PPARG. The blue dashed line indicates the threshold for a one-tailed *t* test below which variants are classified as LOF compared with WT PPARG (*P* < 0.05). Odds ratios and *P* values for T2D case status among individuals carrying benign and LOF variants were calculated as described in *Methods*. *Variants observed only in a single case or control individual.

of T2D. Based on available clinical data, T2D patients who carry such mutations have increased risk of T2D but may lack the highly penetrant, extreme syndromic features observed in mutation carriers who were ascertained based on lipodystrophy that segregates in families.

Compared with the P12A variant, which has a smaller effect size but a 150-fold higher frequency, these rare variants contribute very modestly to the overall population burden of disease.

However, given their larger individual effect sizes, such variants may prove useful for clinical risk prediction. An aggregated score of common genetic variants at 18 loci (including PPARG P12A) provided a 2.6-fold increased risk in individuals in high-score versus low-score groups (12); our data suggests that functional variants in *PPARG* may have effects larger than fivefold. However, only 0.1% of individuals with T2D are estimated to carry such rare variants in *PPARG*, and it is expected that the few individuals in the 0.1% tail of the distribution of risk based on common variants might similarly have larger magnitude of risk. A score that combines common and rare variants will be more predictive than an approach that considers only rare variants, or only common variants, alone.

The data presented here are consistent with the hypothesis that some patients with the common form of T2D have partial defects in adipocyte function attributable to mutations in PPARG. Some of the variants we observed in PPARG cause reduced function in the adipocyte differentiation assay that is as severe as the PPARG mutations associated with FPLD3. Other protein variants in PPARG cause a milder degree of dysfunction and can be rescued to WT levels by elevated doses of PPARG agonists (Fig. 2*B*). Based on the response to rosiglitazone in the adipocyte differentiation assay, we hypothesize that individuals with mild LOF variants in *PPARG* might respond positively to PPARG agonists, because their individual risk of disease was substantially increased by a genetic variant that could be rescued in vitro by PPARG agonists. Administration of rosiglitazone to individuals with severe LOF PPARG mutations who manifest lipodystrophy, insulin resistance, and T2D showed unclear therapeutic benefit for glycemia or insulin resistance, but this might be because mutations conferring complete LOF are not responsive to PPARG agonists (13).

This study has multiple limitations, including a cross-sectional case-control design and the extent of phenotypic characterization of mutation carriers. We are unable to detect any physiologic correlate in LOF *PPARG* variant carriers, which could indicate that the phenotype is not severe, or reflect the lack of more detailed characterization to date such as by dual-energy X-ray absorptiometry-based (DEXA) body composition. The individuals in this study were not ascertained based on extreme phenotypes such as lipodystrophy, nor demonstrate unusual features in the available

Table 2. Clinical and biochemical characteristics of individuals carrying LOF variants in *PPARG*

PPARG variant	Effect on PPARG function	T2D status	Ethnicity	Age	Sex	BMI	Waist-to-hip ratio	SystolicBP	DiastolicBP	Total cholesterol	LDL	HDL	Triglycerides
R165T	Severe	Case	European	40	F	23.6		125	82.5	184			201
R165T	Severe	Case	European	74	M	33.6		150	115	189	100	35	280
F162V	Severe	Case	European	65	M	25.3	0.92	160	85	268	188	53	135
S249*	Severe	Case	European	55	F	21.4		177.5	102.5	228	145	41	211
Q121*	Severe	Control	Caucasian American	36–62[†]	F	20.0[†]		96[†]	67[†]	184[†]	114[†]	65[†]	12[†]
G161D	Severe	Case	European	54	M	25.2	0.94	149	84	256	173	46	183
G161D	Severe	Case	European	82	M	23.7	0.98	150	90	203	125	30	236
V318M	Severe	Case	European	55	F	29.3	0.88						
R425C	Severe	Case	European	50	M	26.1		110	65	180		28	395
P426L	Mild	Case	European	49	F	24.5		134	77	217	137	36	223
E217K	Mild	Case	Hispanic	61	F	21.5	0.90			243	158	39	230
Y278C	Mild	Case	European	69	F	25.8	0.96	146	82	215	129	51	181
R140H	Mild	Case	Hispanic	55	F	31.0	0.96	128	81	202	139	37	126
R140H	Mild	Control	African American	67	F	33.2		130	77	249	186	41	119
M376I	Mild	Case	European	39	M	24.3	0.92	125	89	216	136	44	178
M376I	Mild	Case	European	44	M	26.5	1.03	135	86	193	104	57	164

Units of measurement are as follow: age is in years; systolic and diastolic blood pressure are in millimeters of mercury; total cholesterol, LDL, HDL, and triglycerides are in milligrams per deciliter. BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
[†]This individual had longitudinal measurements obtained over 30 y of follow up. The average values over this period are reported.

GENETICS

data (*SI Appendix*, Fig. 1), but we cannot rule out partial lipodystrophy, which can manifest subtly and easily escape clinical detection. Finally, this study assesses one cellular function of PPARG—adipocyte differentiation. It is possible that some missense variants may alter other cellular functions of PPARG and influence glycemic physiology.

The requirement for experimental characterization before association analysis is consistent with other studies in which functional characterization of rare mutations was needed to discover the relationship to disease (14, 15). This is in contrast to genome-wide association studies of common variants, where the combination of frequency and effect size is sufficient to discover associations without assumptions as to the in vitro assay that will predict clinical impact. Generalization of a genotype-function-phenotype approach to rare variants presents several challenges, in particular the definition of in vitro functional assays that are relevant to the clinical phenotype of interest. With genome sequencing becoming readily available, the key to clinically interpreting rare variants may turn out to be the laboratory assays and computational methods to discriminate benign from functional variants.

Methods

Sample Ascertainment. We studied 19,752 individuals (9,070 cases and 10,682 controls) from multiple ancestries as part of five candidate gene or whole-exome sequencing studies: the Genetics of Type 2 Diabetes (GoT2D) study, the Type 2 Diabetes Genetic Exploration by Next-generation sequencing in multi-Ethnic Samples (T2D-GENES) study, the SIGMA (Slim Initiative in Genomic Medicine for the Americas) T2D Consortium, and the Framingham and Jackson Heart Study Allelic Spectrum project (FHS/JHS). For each study, individuals were drawn from previously described cohorts shown in *SI Appendix*, Table 1. Details on sample sequencing and *PPARG* variant identification are provided in *SI Appendix, Supplementary Methods, Sequencing, Variant Calling, Data QC, and Variant Annotation*. These sequencing studies were approved by the Massachusetts Institute of Technology committee on the use of humans as experimental subjects. Informed consent was obtained from the subjects.

Bioinformatic Assessment of Nonsynonymous *PPARG* Variants. Variants were bioinformatically classified as pathogenic if they met the following three criteria: (*i*) occurred at an evolutionarily conserved site [logarithm of the odds (LOD) >10 based on an alignment of 29 mammalian genomes] (16), (*ii*) computationally predicted as protein damaging by the consensus mutation analysis tool Consensus Deleteriousness Score (Condel) (17), and (*iii*) private to one study individual and not observed in the 1000 Genomes project (18). If they did not meet all of these criteria, they were classified as computationally benign. A second, less stringent bioinformatics classification scheme, where rare variants (i.e., minor allele frequency <0.1%) were classified as pathogenic if they fulfilled criteria *i* and *ii* here above, was also tested.

Rescue of Adipocyte Differentiation by in Vitro *PPARG* Variant Constructs. Each *PPARG* variant was recreated in vitro by PCR mutagenesis and packaged into lentiviruses. These lentiviruses were used to transduce SGBS preadipocytes exposed to a submaximal stimulation for adipocyte differentiation. In this assay, preadipocytes differentiate only when provided with functional, exogenous *PPARG* (Fig. 1C). Details are provided in *SI Appendix, Supplementary Methods, Rescue of Adipocyte Differentiation by in Vitro* PPARG *Variant Constructs*.

High-Throughput Adipocyte Differentiation Assay. To measure adipocyte differentiation at the end of 8 d of exposure to differentiation mixture and *PPARG* variants, cells were fixed in 4% (wt/vol) PFA, washed in PBS, and stained with boron-dipyrromethene (BODIPY; Sigma) (1 µg/mL) to stain lipids and DAPI (1 µg/mL) to stain nuclei. Stained cells were imaged with a high-content fluorescence microscope (Molecular Devices IXM) at 4× at 512 and 484 nm, corresponding respectively to the peak emission spectra of BODIPY and DAPI. The obtained images were analyzed using a custom analysis pipeline developed in CellProfiler (19) to identify total numbers of adipocytes and undifferentiated cells. The ratio of adipocytes to total cells is the percentage of differentiation (Fig. 1A).

Statistical Analysis. In the experimental classification of *PPARG* variants, differentiation scores for variants were compared with differentiation scores for unmutated *PPARG*. Variants were classified experimentally as LOF if they demonstrated decreased ability to stimulate adipocyte differentiation compared with a series of WT controls as assessed by a one-tailed Student *t* test with equal variances and a *P* value threshold of 0.05. Association tests were performed to assess the diabetes risk of variant carriers relative to noncarriers. An identical aggregate gene-based analysis was repeated for each variant annotation: experimental LOF, experimental benign, bioinformatically deleterious, and bioinformatically benign. Details are provided in *SI Appendix, Supplementary Methods, Association Tests*.

1. Deeb SS, et al. (1998) A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. *Nat Genet* 20(3):284–287.
2. Stumvoll M, Häring H (2002) The peroxisome proliferator-activated receptor-γ2 Pro12Ala polymorphism. *Diabetes* 51(8):2341–7.
3. Altshuler D, et al. (2000) The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. *Nat Genet* 26(1):76–80.
4. Barroso I, et al. (1999) Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. *Nature* 402(6764):880–883.
5. Agostini M, et al. (2006) Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance. *Cell Metab* 4(4):303–311.
6. Tennessen JA, et al.; Broad GO; Seattle GO; NHLBI Exome Sequencing Project (2012) Evolution and functional impact of rare coding variation from deep sequencing of human exomes. *Science* 337(6090):64–69.
7. Flannick J, et al. (2013) Assessing the phenotypic effects in the general population of rare variants in genes for a dominant Mendelian form of diabetes. *Nat Genet* 45(11):1380–1385.
8. Sunyaev SR (2012) Inferring causality and functional significance of human coding DNA variants. *Hum Mol Genet* 21(R1):R10–R17.
9. Auclair M, et al. (2013) Peroxisome proliferator-activated receptor-γ mutations responsible for lipodystrophy with severe hypertension activate the cellular renin-angiotensin system. *Arterioscler Thromb Vasc Biol* 33(4):829–838.
10. Jeninga E, Gurnell M (2009) Functional implications of genetic variation in human PPAR [gamma]. *Trends Endocrinol Metab* 20(8):380–387.
11. Visser ME, et al. (2011) Characterisation of non-obese diabetic patients with marked insulin resistance identifies a novel familial partial lipodystrophy-associated PPARγ mutation (Y151C). *Diabetologia* 54(7):1639–1644.
12. Meigs JB, et al. (2008) Genotype score in addition to common risk factors for prediction of type 2 diabetes. *N Engl J Med* 359(21):2208–2219.
13. Savage DB, et al. (2003) Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. *Diabetes* 52(4):910–917.
14. Ji W, et al. (2008) Rare independent mutations in renal salt handling genes contribute to blood pressure variation. *Nat Genet* 40(5):592–599.
15. Bonnefond A, et al.; Meta-Analysis of Glucose and Insulin-Related Traits Consortium (MAGIC) (2012) Rare MTNR1B variants impairing melatonin receptor 1B function contribute to type 2 diabetes. *Nat Genet* 44(3):297–301.
16. Lindblad-Toh K, et al.; Broad Institute Sequencing Platform and Whole Genome Assembly Team; Baylor College of Medicine Human Genome Sequencing Center Sequencing Team; Genome Institute at Washington University (2011) A high-resolution map of human evolutionary constraint using 29 mammals. *Nature* 478(7370):476–482.
17. González-Pérez A, López-Bigas N (2011) Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel. *Am J Hum Genet* 88(4):440–449.
18. Abecasis GR, et al.; 1000 Genomes Project Consortium (2010) A map of human genome variation from population-scale sequencing. *Nature* 467(7319):1061–1073.
19. Carpenter AE, et al. (2006) CellProfiler: Image analysis software for identifying and quantifying cell phenotypes. *Genome Biol* 7(10):R100.